{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:30:24Z","timestamp":1768915824702,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft (DE)","award":["SFB650 TPZ06"],"award-info":[{"award-number":["SFB650 TPZ06"]}]},{"name":"IMI JU-funded projekt BeTheCure","award":["115-142-2"],"award-info":[{"award-number":["115-142-2"]}]},{"name":"Bundesministerium f\u00fcr Bildung und Forschung (DE)","award":["01ZX1306B"],"award-info":[{"award-number":["01ZX1306B"]}]},{"DOI":"10.13039\/501100001664","name":"Leibniz-Gemeinschaft","doi-asserted-by":"publisher","award":["ScienceCampus Chronic Inflammation"],"award-info":[{"award-number":["ScienceCampus Chronic Inflammation"]}],"id":[{"id":"10.13039\/501100001664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1692-y","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T19:23:17Z","timestamp":1535570597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus"],"prefix":"10.1186","volume":"20","author":[{"given":"Ursula","family":"Schulte-Wrede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"S\u00f6rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim R.","family":"Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"H\u00e4upl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Hirseland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Steinbrich-Z\u00f6llner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Radbruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Syrbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6490-2992","authenticated-orcid":false,"given":"Andreas","family":"Gr\u00fctzkau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"1692_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379\u201390.","journal-title":"Lancet"},{"key":"1692_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/ket387 .","journal-title":"Rheumatology (Oxford)"},{"key":"1692_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00296-002-0237-4","volume":"23","author":"E Feldtkeller","year":"2003","unstructured":"Feldtkeller E, Khan M, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23:61\u20136.","journal-title":"Rheumatol Int"},{"key":"1692_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/ard.35.3.267","volume":"35","author":"HF Hill","year":"1976","unstructured":"Hill HF, Hill AG, Bodmer JG. Clinical diagnosis of ankylosing spondylitis in women and relation to presence of HLA-B27. Ann Rheum Dis. 1976;35:267\u201370.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","volume":"1","author":"DA Brewerton","year":"1973","unstructured":"Brewerton DA, et al. Ankylosing spondylitis and HL-A 27. Lancet. 1973;1:904\u20137.","journal-title":"Lancet"},{"key":"1692_CR6","first-page":"74","volume":"55","author":"A Trull","year":"1984","unstructured":"Trull A, Ebringer A, Panayi G, Ebringer R, James DC. HLA-B27 and the immune response to enterobacterial antigens in ankylosing spondylitis. Clin Exp Immunol. 1984;55:74\u201380.","journal-title":"Clin Exp Immunol"},{"key":"1692_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1759720X09359728","volume":"2","author":"LC Coates","year":"2010","unstructured":"Coates LC, Marzo-Ortega H, Bennett AN, Emery P. Anti-TNF therapy in ankylosing spondylitis: insights for the clinician. Ther Adv Musculoskelet Dis. 2010;2:37\u201343.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"Suppl 3","key":"1692_CR8","doi-asserted-by":"publisher","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8\u201318.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR9","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.24001","volume":"59","author":"J Braun","year":"2008","unstructured":"Braun J, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59:1270\u20138.","journal-title":"Arthritis Rheum"},{"key":"1692_CR10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.081033","volume":"36","author":"B Dijkmans","year":"2009","unstructured":"Dijkmans B, et al. Etanercept in the long-term treatment of patients with ankylosing spondylitis. J Rheumatol. 2009;36:1256\u201364. https:\/\/doi.org\/10.3899\/jrheum.081033 .","journal-title":"J Rheumatol"},{"key":"1692_CR11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","volume":"74","author":"A Deodhar","year":"2015","unstructured":"Deodhar A, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015;74:757\u201361.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651\u201365.","journal-title":"Blood"},{"key":"1692_CR15","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.4049\/jimmunol.147.12.4229","volume":"147","author":"C Ware","year":"1991","unstructured":"Ware C, et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol. 1991;147:4229\u201338.","journal-title":"J Immunol"},{"key":"1692_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jlb.58.2.249","volume":"58","author":"A Mason","year":"1995","unstructured":"Mason A, et al. Regulation of NK cells through the 80-kDa TNFR (CD120b). J Leukoc Biol. 1995;58:249\u201355.","journal-title":"J Leukoc Biol"},{"key":"1692_CR17","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1523\/JNEUROSCI.22-08-03025.2002","volume":"22","author":"L Yang","year":"2002","unstructured":"Yang L, Lindholm K, Konishi Y, Li R, Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci. 2002;22:3025\u201332.","journal-title":"J Neurosci"},{"issue":"478","key":"1692_CR18","first-page":"1","volume":"4","author":"DL Faustman","year":"2013","unstructured":"Faustman DL, Davis M. TNF receptor 2 and disease: autoimmunity and regenerative medicine. Front Immunol. 2013;4(478):1\u20138.","journal-title":"Front Immunol"},{"key":"1692_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1742-4658.2011.08017.x","volume":"278","author":"PJ Naude","year":"2011","unstructured":"Naude PJ, den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk. FEBS J. 2011;278:888\u201398.","journal-title":"FEBS J"},{"key":"1692_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165\u201378.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","volume":"160","author":"G Haberhauer","year":"2010","unstructured":"Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr. 2010;160:220\u20134.","journal-title":"Wien Med Wochenschr"},{"key":"1692_CR22","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.","journal-title":"Arthritis Res Ther"},{"key":"1692_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/BOR.0b013e32835257c5","volume":"24","author":"S Arends","year":"2012","unstructured":"Arends S, van der Veer E, Kallenberg CG, Brouwer E, Spoorenberg A. Baseline predictors of response to TNF-alpha blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol. 2012;24:290\u20138.","journal-title":"Curr Opin Rheumatol"},{"key":"1692_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","volume":"49","author":"PA Lord","year":"2010","unstructured":"Lord PA, et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology biologics register. Rheumatology (Oxford). 2010;49:563\u201370.","journal-title":"Rheumatology (Oxford)"},{"key":"1692_CR25","doi-asserted-by":"publisher","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1:e000017.","journal-title":"RMD Open"},{"key":"1692_CR26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665\u201370.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR27","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit M, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276\u201381.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","volume":"46","author":"M Seitz","year":"2007","unstructured":"Seitz M, Wirthmuller U, Moller B, Villiger PM. The \u2212308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46:93\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1692_CR29","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2217\/pgs.12.133","volume":"13","author":"Q Tong","year":"2012","unstructured":"Tong Q, et al. TNF-alpha \u2212857 and \u22121031 polymorphisms predict good therapeutic response to TNF-alpha blockers in Chinese Han patients with ankylosing spondylitis. Pharmacogenomics. 2012;13:1459\u201367.","journal-title":"Pharmacogenomics"},{"key":"1692_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"1692_CR31","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"1692_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/cyto.a.20505","volume":"73","author":"M Steinbrich-Zollner","year":"2008","unstructured":"Steinbrich-Zollner M, et al. From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases. Cytometry A. 2008;73:333\u201340.","journal-title":"Cytometry A"},{"key":"1692_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/cyto.a.22626","volume":"87","author":"T S\u00f6rensen","year":"2015","unstructured":"S\u00f6rensen T, Baumgart S, Durek P, Gr\u00fctzkau A, H\u00e4upl T. ImmunoClust\u2014an automated analysis pipeline for the identification of immunophenotypic signatures in high-dimensional cytometric datasets. Cytometry A. 2015;87:603\u201315.","journal-title":"Cytometry A"},{"key":"1692_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10067-015-2949-3","volume":"34","author":"J Reveille","year":"2015","unstructured":"Reveille J. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015;34:1009\u201318.","journal-title":"Clin Rheumatol"},{"key":"1692_CR35","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.24838","volume":"61","author":"MK de Vries","year":"2009","unstructured":"de Vries MK, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009;61:1484\u201390.","journal-title":"Arthritis Rheum"},{"key":"1692_CR36","first-page":"2078","volume":"34","author":"M Luc","year":"2007","unstructured":"Luc M, et al. C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol. 2007;34:2078\u201381.","journal-title":"J Rheumatol"},{"key":"1692_CR37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/ng.873","volume":"43","author":"D Evans","year":"2011","unstructured":"Evans D, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43:761\u20137.","journal-title":"Nat Genet"},{"key":"1692_CR38","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3899\/jrheum.101128","volume":"38","author":"S Arends","year":"2011","unstructured":"Arends S, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol. 2011;38:1644\u201350.","journal-title":"J Rheumatol"},{"key":"1692_CR39","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/annrheumdis-2013-203824","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis. 2014;73:2137\u201343.","journal-title":"Ann Rheum Dis"},{"key":"1692_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-017-8608-5","volume":"53","author":"G Carvajal Alegria","year":"2017","unstructured":"Carvajal Alegria G, Gazeau P, Hillion S, Daien CI, Cornec DYK. Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases? Clinic Rev Allerg Immunol. 2017;53:219\u201336.","journal-title":"Clinic Rev Allerg Immunol"},{"key":"1692_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3109\/s10165-009-0160-6","volume":"19","author":"T Aramaki","year":"2009","unstructured":"Aramaki T, et al. A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol. 2009;19:245\u201352.","journal-title":"Mod Rheumatol"},{"key":"1692_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0022-510X(89)90222-0","volume":"94","author":"Z Vranes","year":"1989","unstructured":"Vranes Z, Poljakovic Z, Marusic M. Natural killer cell number and activity in multiple sclerosis. J Neurol Sci. 1989;94:115\u201323.","journal-title":"J Neurol Sci"},{"key":"1692_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1365-2133.2003.05319.x","volume":"149","author":"AL Cameron","year":"2003","unstructured":"Cameron AL, Kirby B, Griffiths CE. Circulating natural killer cells in psoriasis. Br J Dermatol. 2003;149:160\u20134.","journal-title":"Br J Dermatol"},{"key":"1692_CR44","first-page":"71","volume":"10","author":"PW Ewan","year":"1983","unstructured":"Ewan PW, Barrett HM, Pusey CD. Defective natural killer (NK) and killer (K) cell function in systemic lupus erythematosus. J Clin Lab Immunol. 1983;10:71\u20136.","journal-title":"J Clin Lab Immunol"},{"key":"1692_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.autrev.2011.04.017","volume":"10","author":"P Conigliaro","year":"2011","unstructured":"Conigliaro P, Scrivo R, Valesini G, Perricone R. Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev. 2011;10:577\u201381.","journal-title":"Autoimmun Rev"},{"key":"1692_CR46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/0167-5699(96)30009-1","volume":"17","author":"M Lopez-Botet","year":"1996","unstructured":"Lopez-Botet M, Moretta L, Strominger J. NK-cell receptors and recognition of MHC class I molecules. Immunol Today. 1996;17:212\u20134.","journal-title":"Immunol Today"},{"key":"1692_CR47","first-page":"193","volume":"8","author":"T Mousavi","year":"2009","unstructured":"Mousavi T, et al. Phenotypic study of natural killer cell subsets in ankylosing spondylitis patients. Iran J Allergy Asthma Immunol. 2009;8:193\u20138.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"1692_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/intimm\/dxh270","volume":"17","author":"N Azuz-Lieberman","year":"2005","unstructured":"Azuz-Lieberman N, et al. The involvement of NK cells in ankylosing spondylitis. Int Immunol. 2005;17:837\u201345.","journal-title":"Int Immunol"},{"key":"1692_CR49","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1002\/art.21395","volume":"52","author":"AT Chan","year":"2005","unstructured":"Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005;52:3586\u201395.","journal-title":"Arthritis Rheum"},{"key":"1692_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/cyto.b.20549","volume":"80","author":"R Scrivo","year":"2011","unstructured":"Scrivo R, Morrone S, Spadaro A, Santoni A, Valesini G. Evaluation of degranulation and cytokine production in natural killer cells from spondyloarthritis patients at single-cell level. Cytometry B Clin Cytom. 2011;80:22\u20137.","journal-title":"Cytometry B Clin Cytom"},{"key":"1692_CR51","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2567.2005.02235.x","volume":"116","author":"EG Addison","year":"2005","unstructured":"Addison EG, et al. Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology. 2005;116:354\u201361.","journal-title":"Immunology"},{"key":"1692_CR52","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cyto.990110316","volume":"11","author":"EF Srour","year":"1990","unstructured":"Srour EF, Leemhuis T, Jenski L, Redmond R, Jansen J. Cytolytic activity of human natural killer cell subpopulations isolated by four-color immunofluorescence flow cytometric cell sorting. Cytometry. 1990;11:442\u20136.","journal-title":"Cytometry"},{"key":"1692_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1189\/jlb.0109040","volume":"86","author":"D Gibbings","year":"2009","unstructured":"Gibbings D, Befus AD. CD4 and CD8: an inside-out coreceptor model for innate immune cells. J Leukoc Biol. 2009;86:251\u20139.","journal-title":"J Leukoc Biol"},{"key":"1692_CR54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/antib4010048","volume":"4","author":"R Fischer","year":"2015","unstructured":"Fischer R, Kontermann RE, Maier O. Targeting sTNF\/TNFR1 signaling as a new therapeutic strategy. Antibodies. 2015;4:48\u201370.","journal-title":"Antibodies"},{"key":"1692_CR55","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.4049\/jimmunol.163.8.4105","volume":"163","author":"KA Solomaon","year":"1999","unstructured":"Solomaon KA, Pesti N, Wu G, Newton RC. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol. 1999;163:4105\u20138.","journal-title":"J Immunol"},{"key":"1692_CR56","first-page":"51","volume":"35","author":"D Wallach","year":"1991","unstructured":"Wallach D, et al. Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl. 1991;35:51\u20137.","journal-title":"Agents Actions Suppl"},{"key":"1692_CR57","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12967-015-0620-z","volume":"13","author":"U Meusch","year":"2015","unstructured":"Meusch U, et al. In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis. J Transl Med. 2015;13:256. https:\/\/doi.org\/10.1186\/s12967-015-0620-z .","journal-title":"J Transl Med"},{"key":"1692_CR58","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.158.8.3869","volume":"158","author":"JK Pinckard","year":"1997","unstructured":"Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol. 1997;158:3869\u201373.","journal-title":"J Immunol"},{"key":"1692_CR59","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.4049\/jimmunol.152.7.3550","volume":"152","author":"M Higuchi","year":"1994","unstructured":"Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol. 1994;152:3550\u20138.","journal-title":"J Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1692-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T17:44:52Z","timestamp":1693849492000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1692-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1692-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"27 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the 1964 Declaration of Helsinki and approved by the \u201cCharit\u00e9 University Medicine ethics committee I of Charit\u00e9 Campus Mitte\u201d, and all patients provided written informed consent to participate in the study. Furthermore, we declare that this manuscript contains no information or images that could lead to identification of a study participant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"191"}}